Life Sciences Tools and Services
Company Overview of EpiVax, Inc.
EpiVax, Inc. engages in the development and implementation of computational immunology analytical tools for epitope discovery, de-immunization, and vaccine design applications. The company utilizes its tools for reengineering therapeutic proteins and designing new vaccines to support its clients’ research and development activities, as well as to develop its own pipeline of therapeutic proteins and vaccine candidates. It engages in providing epitope discovery and de-immunization services to researchers and developers in industry and academia; establishing collaborations with pharmaceutical, vaccine, and biotechnology companies focused on biological targets; and conducting internal discovery ...
146 Clifford Street
Providence, RI 02903
Founded in 1998
Key Executives for EpiVax, Inc.
Chief Operating Officer and Chief Information Officer
Director of Molecular Immunology
Scientific Director of Vaccine Research
Compensation as of Fiscal Year 2013.
EpiVax, Inc. Key Developments
Biotest AG and EpiVax, Inc. Announce Collaborative Research Agreement
Dec 3 13
Biotest AG and EpiVax, Inc. announced a new collaborative research agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by developing inhibitory antibodies. The formation of inhibitory antibodies against the Coagulation factor VIII reduces its efficacy and may lead to severe bleeding disorders. Immunogenicity suppression will be also achieved through integration of EpiVax' proprietary Tregitope, an immune-modulating technology, with the FVIII treatment. A tolerized and de-immunized version of factor VIII would allow patients and their families to experience the benefits of FVIII treatment, which does not induce a reaction of the immune system (no immunogenicity) without the fear of developing inhibitory antibodies ('inhibitors') against the therapeutic factor VIII. Studies carried out by EpiVax and collaborators indicate that Tregitope may be useful for reducing the antibody formation (inducing tolerance) to transplants, protein drugs, and allergens by 'Tregitopes'.
EpiVax, Inc. Announces New Collaborative Research Agreement with Novozymes Biopharma AU Limited
Feb 12 13
EpiVax, Inc. announced a new Collaborative Research Agreement with Novozymes Biopharma AU Limited. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes' proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy. EpiVax has compiled substantial evidence linking Tregitopes to the activation of natural regulatory T cells. By selectively activating these natural regulatory T cells, Tregitopes can dampen unwanted immune responses. Preliminary studies carried out by EpiVax and collaborators indicate that Tregitopes may be useful for inducing tolerance to transplants, protein drugs, and blood replacement therapies, as well as for the treatment of allergies. EpiVax believes Tregitopes may explain the effectiveness of intravenous immunoglobulin G (IVIG), widely utilized as an autoimmune treatment. The initial disease target for Tregitope therapy with the albumin-Tregitope fusion will be Type 1 diabetes (T1D).
EpiVax, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013
Dec 18 12
EpiVax, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 . Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|